又一国产创新药“头对头”试验成功!国内医药研发实力再次彰显

制药网
23 Jul

【制药网 行业动态】在全球医药研发的激烈竞争中,“头对头” 试验成为衡量创新药实力的关键战场。近期,丽珠集团的 1 类创新生物药 LZM012 在中重度斑块型银屑病治疗的 Ⅲ 期临床试验中成功达到主要研究终点,并且是直接采用 “头对头” 研究设计,对标全球 IL-17A 靶点药物 —— 诺华的司库奇尤单抗(商品名:可善挺),这一成果振奋人心,标志着国产创新药在国际舞台上取得了重大突破。​“头对头”...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10